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The human gut microbiome is considered an organ in its entirety and has been the
subject of extensive research due to its role in physiology, metabolism, digestion, and
immune regulation. Disequilibria of the normal microbiome have been associated with the
development of several gastrointestinal diseases, but the exact underlying interactions
are not well understood. Conventional in vivo and in vitro modelling systems fail to faith-
fully recapitulate the complexity of the human host–gut microbiome, emphasising the
requirement for novel systems that provide a platform to study human host–gut micro-
biome interactions with a more holistic representation of the human in vivo microenviron-
ment. In this review, we outline the progression and applications of new and old
modelling systems with particular focus on their ability to model and to study host–micro-
biome cross-talk.
Introduction
The development of novel prognostic tools and effective therapeutic strategies relies upon a profound
understanding of the molecular mechanisms involved in health and disease, including inﬂuences
from the microbiome [1,2]. For example, the microbiome that inhabits the human gut is integral in
regulating normal gut homeostasis. Such physiological functions include aiding digestion, producing
metabolites from undigested ﬁbre, regulating drug metabolism, adapting immune responses, and
protecting the host from pathogens and infections [3–5]. The realisation that commensal and
pathogenic bacteria play a role in dysbiosis, disease development, and chronic disorders [3–5] places
an emphasis on gaining a deeper understanding of the underlying mechanisms involved in physio-
logical and pathophysiological host–microbiome cross-talk. The complexity of a holistic understanding
of these cause-and-effect relationships in humans makes human studies complicated and somewhat
limited, most notably because of the challenges in accessing the human gut, making disease-modelling
essential. Preclinical animal models and in vitro 2D cell culture studies have provided extensive
insights into the physiological and pathophysiological processes that underpin disease. However,
as they do not faithfully represent the human body, they are not suitable models to evaluate
all research questions nor model drug efﬁcacy. Moreover, the high number of therapeutic compounds
that fail to translate in clinical trials [6,7] highlights the need and importance for models that
are more physiologically relevant to the human body, in order to personalise treatments and
better predict patient outcomes. In this review, we discuss the advantages and disadvantages
of conventional modelling systems. Furthermore, we review the advantages and contributions
of 3D organoid culture and systems such as organ-on-a-chip that better recapitulate the in vivo
human body and provide a better understanding of cell–cell interactions and the host–gut microbiome
cross-talk that occurs in health and disease. The advantages and disadvantages of the systems
discussed in this review are outlined in Table 1. Figure 1 provides schematic representation of these
systems.
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Table 1. Advantages and disadvantages of current culturing techniques with respect to host–microbiome
interaction Part 1 of 3
Type of assay Advantages Disadvantages
2D ethos • Inexpensive, easy-to-use, data generated
quickly [9,10].
• Retain many genetic, epigenetic, and gene
expression features of human cancer [9,10].
• Established from metastatic tumours,
restricting their use in cancer progression
studies and early drug interventions [149].
• Not an accurate representation of the
in vivo 3D microenvironment [3,11].
• Drug doses that are effective in 2D culture
often result in poor efficacy when scaled in
to humans [10-13].
• 2D culture exerts selection pressures on
cells that alter morphology and gene
expression [10].
Transwell • Easily implemented, low-cost assay [145].
• High throughput [145].
• Can be used to compare metastatic potential of
cells [145].
• Provides thorough analysis of cells ability to
migrate and sense a chemo-attractant [145].
• Can be used to investigate cell invasion [146].
• Low physiological relevance [79].
• Migration and invasion assays can result in
conflicting data [82].
• Unstirred water layer may decrease the
permeability rate of lipid soluble
molecules [82].
• Cells are grown in a static media, and there
is no shear stress forced on the cells [147].
Organoids • Near-physiological model for epithelial tissue
containing heterogeneous cell populations —
maintaining integrity of the in vivo structure [49].
• Enable analysis of cell–cell and cell–matrix
interactions, while maintaining mechanical
properties, gene expression, and metabolic
profiles [148].
• Ex vivo culture bridges gap between cell culture
and animal modelling [149].
• Can microinject microbes into the lumen of
organoids to study host–pathogen
interactions [63].
• Organoid/enteroids can be grown in 2D
monolayers on Transwell inserts such that
microbes can be exposed to the apical cell
surface simultaneously with immune cells at the
basolateral surface, more representative of the
in vivo human microenvironment, and permits
human host–pathogen studies [42,75–77].
• Reductionist approach — epithelial cells grow
without its native microenvironment [49].
• Wrong side of epithelium exposed to




• Realistic vasculature morphology and
physiology with diffusion transport [81].
• SynVivo’s inflammatory model has been
successfully validated against in vivo
studies [85,86].
• Excellent correlation with rolling velocities,
adhesion patterns, and migratory
processes [85,86].
• A SynVivo produced chip can partly mimic the
in vivo blood–tumour barrier [82].
• Still cannot be used without conjunction of
animal testing [150].
• Hard-to-remove bubbles can form —
rendering the chip unusable [81].
• Not yet applicable to studying microbiome
interaction.
Tissue slices • Has the ability to assess the role of the tumour
microenvironment on tumour growth and
survival [92].
• Freshly resected tissue slices are viable for at
least 24 h [92].
• Tissues start to deteriorate after 3 weeks in
culture (tissue-dependent) [152].
• Donor-to-donor variability [152].
• Difficulty in monitoring cells beyond the
depth of confocal microscopy (unless cells
are isolated for analysis) [152].
Continued
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Table 1. Advantages and disadvantages of current culturing techniques with respect to host–microbiome
interaction Part 2 of 3
Type of assay Advantages Disadvantages
• Contains a higher level of biological
organisation, and has cell–cell interaction, which
may better reflect the response of the target
organ [151].
• Can be used to represent all regions within a
tissue [91,92].
• Effect of microbiome and pathogenic bacteria
on epithelial integrity, permeability, and
contractility can be examined when tissue slices
are used in conjunction with Ussing chambers
[95,98,101].
• The system does not reflect the effects of
in vivo systemic factors [152].
• Further work is required to maintain
anaerobic microbes in intestine [94].
Organ/tissue
baths
• Versatile, simple, and reproducible assay that is
suitable for all organ sizes [103,104].
• Ability to measure concentration-dependent
changes to isometric contractions [103].
• Experiment is in real time — can rapidly make
conclusions and troubleshoot [103].
• 3R’s — multiple tissues can be prepared from
one animal [103].
• Scope to study probiotic and pathogenic
microbes ex vivo [107].
• Organs/tissues may experience different
degrees of damage during surgical
removal [103].
• Organs/tissues may also have different
viability lengths [103].
• Responsiveness of tissues may alter —
time controls may be necessary [103].
• New tissue required for each experiment
[105,106] hindering studies that follow
genetic backgrounds.
Organ-on-a-chip • Enables research into physiological and
pathophysiological responses of tissues, with
interaction from microbes [153,154].
• Can be exploited to complement animal
studies and even bypass animal modelling in
the future [153].
• Accurately predict pharmacological effects in
patients [153,154].
• Raw materials used are relatively cheap [153].
• Cheap, versatile, precise, and reliable system [114].
• Microengineering complexities [155],
cleanrooms, and pumps can be
costly [153].
• Surface area and roughness of chip and
formation of bubbles can affect capillary
forces and flow rate of the microfluid,
which can damage cells [154].
• Matrix degrades when culturing time
increases, affecting cell functionality [153].
• Cannot reflect chronic diseases, adaptive
immune responses, or mirror complicated
behaviours of the endocrine, skeletal, or
nervous systems [156].
• Human testing is still necessary [155,156].
Quasi-Vivo®
(Kirkstall)
• Provides a flexible and easy system that enables
long-term co-culture of multiple cell types and
improves cell viability [157].
• Has the ability to apply high flow rates and
create high nutrient turnover to cells without
imposing high shear stress or turbulent
flow [158].
• Enables microwell protocols to be transferred
directly to the bioreactor modules without the
need to redesign cell culture [130].
• Control of oxygen tension to visually represent
conditions at the surface and within
tumours [130].
• Currently has a limited ability to model all
tissue types [130].
• The allometric aspects of dosage are
unknown [130].
• Not applicable to microbiome studies.
HuMiX module • Can simultaneously establish aerobic and
anaerobic conditions and measure oxygen
levels in real time [133].
• Effects of individual and combinations of
bacteria on host physiology are possible [134].
• Cell types cannot fully represent the cellular
makeup of the entire intestinal tract
[133,134].
Continued
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2D culture and in vivo animal models to study human
disease
Human cell lines have had a fundamental role in determining the importance of pathways involved in disease
and have been a good platform for screening and characterising drug therapeutics [8]. Cell lines retain many
genetic, epigenetic and gene expression features of human disease [9,10]. However, they fail to represent the in
vivo 3D microenvironment, induce cell differentiation [11,12], perform tissue-speciﬁc functions [11,13,14], and
do not represent the natural cell heterogeneity that compose primary tumours [9]. In addition, it is often found
that drug doses that are effective in 2D culture result in poor efﬁcacy when scaled to humans [6,15–17]. Many
of these limitations are addressed by genetically engineered mouse models (GEMMs). GEMMs have been an
extremely useful tool for studying early and chronic stages of human disease [8], as they share similarities in
anatomy, physiology, and genetics [18–22]. However, their use for investigating host–microbiome interactions
is limited by the differences in lifespan, variations in diet, and microbiome populations [23]. The inability of
these systems to study the cause-and-effect relationships of the host–microbiome interactions in a meaningful
way is driving the development of systems to overcome this issue.
Table 1. Advantages and disadvantages of current culturing techniques with respect to host–microbiome
interaction Part 3 of 3
Type of assay Advantages Disadvantages
• Can co-culture individual cell lines that are in
close proximity to other cell types, yet can be
exposed to independent conditions — great for
understanding microecology of gut [134].
• Ecology of communities can be manipulated,
meaning transition states can be studied —
potential for identification of early biomarkers in
disease linked with dysbiosis [134].
Figure 1. Current cell modelling systems and their potential to model host-microbiome cross-talk.
Schematic representation of current cell culturing techniques available and their ability to model host–microbiome interactions.
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Cell culturing systems for studying the human microbiome
The gastrointestinal (GI) tract contains a ﬂora of commensal bacteria, known as the microbiome [24]. The
living gut microbiome has been of increasing interest in recent years, as its role in the regulation of the
immune system, local barrier functions, homeostasis, and tissue regeneration and also in the development of
certain diseases (e.g. Crohn’s disease, inﬂammatory bowel disease, and coeliac disease) are not fully understood
[3,5,25]. Additionally, it is known that the gut microbiome can inﬂuence drug absorption and metabolism
[3,26]. Thus, it is paramount that host–gut microbiome interactions are elucidated.
Advancements in techniques for culturing cells have been critical for identifying and understanding cell
involvement in disease initiation. In vitro sphere-forming assays were among the ﬁrst techniques adopted to
study these interactions. The sphere-forming assays were initially developed to study neural stem cells [27] and
were later developed to culture mammary stem cells [28]. In these cultures, cells aggregate together to form 3D
spheroid structures, which can then be utilised to determine stem cell behaviour of both human and animal
cell populations [29,30]. Typically, the study of human GI disease has relied upon culturing intestinal epithelial
cells in static well plate assays. For example, Transwell culture has been used to grow a polarised monolayer of
human cell lines [31] on a nanoporous insert [3]. Microbial cells, probiotic [32–35] or pathogenic [36–39], can
then be added to the apical cell surface. To gain further insights, immune cells can be simultaneously added to
the basolateral side of the monolayer culture [31,40–42]. Transwell culture is limited however, as cultured epi-
thelial cells do not produce functional specialised cell types [12,43]. Consequently, a substantial amount of
research has focused on the development of a 3D culturing technique, initially using individual murine intes-
tinal stem cells [44,45] and also patient-derived tissues and human stem cells [46–48] that grow into self-
renewing organoids that encompass the structure, and all cell types of the in vivo intestinal crypt, providing a
more human-relevant model.
The progression from 2D to 3D organoid culture
Long-term organoid culturing has been a major breakthrough in research and is now an extensively used tool
for studying both basic and clinical biology [49–51]. Advancement in technology has enabled culturing of the
stomach [52–54], pancreas [55–57], liver [58], prostate [59,60], oesophagus [46,61], gall bladder [62,63], and
taste buds [64]. Additionally, CRISPR-Cas9 technology has been exploited to induce gene editing in intestinal
organoids that mimics the sequential loss and gain of functions of genes involved in human colorectal cancer
[65], which, after in orthotopic engraftment, could metastasise to the liver [66,67]. Thus, organoid models can
be used to study advanced aspects of cancer development in a more complexed in vivo scenario. Organoid
culture has been exploited to investigate host–gut microbiome interactions by microinjection of microbes to the
lumen of organoids (apical surface, as this mimics aspects of microbial infection in vivo) or basally by the add-
ition of microbes to the media [63]. The potential of organoids as a model for studying host–microbial interac-
tions has been demonstrated using human gastric organoids and the pathogenic microbe, Helicobacter pylori
[54,68,69], that is known to cause infection, ulceration, and gastric cancer in humans [70]. Apical infection of
gastric organoids with H. pylori recapitulates known hallmarks of infection, including a marked increase in
mucus-secreting cell expression, induction of cytokine production via up-regulation of NF-κB (known to
induce gastritis), and production of the H. pylori virulence factor CagA (cytotoxin-associated gene A), which is
associated with motogenesis and tumour progression [71,72]. Other studies have been able to efﬁciently infect
human-derived organoids in a similar manner with a range of known pathogens, including Salmonella typhi-
murium [63], Clostridium difﬁcile [73,74], and rotaviruses [75]. Thus, these studies present a valuable near-
physiological modelling system in which to begin deciphering the complex interactions between host epithelium
and infectious agents. Additionally, several recent studies have improved the human relevance of Transwell cul-
tures. For example, Transwells have been adapted to grow human small intestinal and colonic organoids in
monolayers on Transwell membranes that support microbial (Escherichia coli [42,76,77] and norovirus [78])
adherence at the cell surface, as seen in vivo. The above studies have provided an informative platform that can
be exploited to use patient-derived tissues to study donor-speciﬁc disease progression, host responses to enteric
pathogens, and provide a platform to develop personalised treatments.
However, like any other system, organoid culture has its limitations. In instances where microbes are added
to culture medium, microbial overgrowth often occurs, which can damage the epithelium and can hinder long-
term co-culture, this is also the case with co-culturing human cell lines with microbes using Transwells [3,43]
and, thus, should be avoided where possible. It is not possible to exert peristalsis-like motions (which is
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required in vivo to sustain intestinal differentiation and conﬁne microbial overgrowth [14]) to the cells cultured
in Transwell or organoid culture. And the reductionist approach of organoid culture limits the full potential of
this method as epithelial cells grow without their native microenvironment, and the true contributions from
the stroma, extracellular matrix (ECM), oxygen, vasculature, immune system, and the microbiome cannot be
truly assessed [49,79]. This ultimately impedes the understanding of the precise molecular mechanisms
involved in transition from healthy to disease states and limits the potential efﬁcacy of interventions when
translated to clinic.
It is evident that models, which reﬂect the holistic environment, are crucial to better predict patient out-
comes to therapy, understand the mechanisms that underpin disease and the role environmental factors, such
as diet, have on physiology and pathophysiology [12]. The integration of microﬂuidics with living biological
systems has paved the way for new techniques such as the exciting ‘organ-on-a-chip’ concepts, which aims at
developing advanced in vitro models that replicate the key features of human tissues and organs [80]. The cul-
turing methods outlined below are discussed in increasing order of their ability to represent the in vivo environ-
ment and its suitability to study host–microbe interactions.
SynVivo®
SynVivo microﬂuidic models have been developed to study human tissue microvasculature, cell–cell, and cell–
drug interactions in a 3D setting, in the context of in vivo-relevant ﬂow and pressures [81]. Currently, SynVivo
models have four independent assays that represent the blood–brain barrier [82–84], cancer [85], inﬂammation,
[86,87] and toxicology. SynVivo devices utilise polydimethylsiloxane (PDMS) chambers that comprise a micro-
ﬂuidic map of vasculature with spaces that can be lined with ECM. For example, endothelial cells can be cul-
tured on ﬁbronectin-coated channels and activated using cytokines. Endothelial cell interactions with white
blood cells can then be assessed in real time by the injection of cells into the system [81]. Synthetic network
assays can also recapitulate in vivo leaky vasculature associated with tumourigenesis and thus can be utilised to
study both basic and applied research [81]. To date, SynVivo chips have not yet been developed to study micro-
bial interactions; however, its ability to recreate a realistic vasculature network surrounding a tissue will make a
profound advancement in modelling in vivo 3D environments.
Tissue slices
Precision-cut tissue slices (PCTS) are a useful tool for metabolic, pharmacology, and toxicological studies [88–
90]. Predominately used to model solid organs (e.g. liver and kidney) and agarose-embedded non-solid organs
such as the intestine [91,92], uniform tissue slices are cut and incubated in media in 6- or 12-well plates and
exposed to atmospheric conditions [92]. PCTS are believed to have advantages over organoids and
organ-on-a-chip (discussed later), as they represent all regions of the tissue [91]. It has been reported that
murine intestine is maintained for 6 days in the presence of normal neuronal, muscular, and mucosal struc-
tures with contractibility functions and some immune responses, therefore, representing a more holistic intes-
tinal organ [93]. Additionally, in the absence of antibiotic media, some aerobic commensal microbes can be
maintained [93]. Although this system holds great promise to study holistically the complex mechanisms that
underpin healthy gut functions and disease in a 3D physiologically relevant environment, further work is
required to maintain anaerobic microbes that are predominately found within the intestinal environment [94].
In addition to maintaining tissue slices in media, epithelial integrity, neural activity, ion/nutrient/drug transport
[95–97], and the effect of microbiota and pathogenic bacteria on these processes [98–101] can be examined
using analytical tools, such as the Ussing chamber. As this tool compartmentalises the apical and basolateral
surfaces of the tissue, each surface can be exposed to independent physiological solutions [95], representative of
the in vivo microenvironment. The potential of the Ussing chamber to investigate host–pathogen interactions
was highlighted when co-culture of human cell lines with the infection-causing bacteria, C. difﬁcile, extensively
impaired epithelial barrier function and elicited cytotoxic immune responses which contributes to C. difﬁcile-
mediated pathogenesis [101]. One limitation of the Ussing chamber, however, is that intestinal tissue viability
is often limited to 3 h which limits long-term optimal tissue function studies [102].
Organ baths
Organ bath assays play important roles in evaluating concentration–response relationships in a variety of
tissues, predominately contractile organs. The primary advantage of organ baths is that live tissue is cultured
that continues to function as a whole unit with respect to contractions visualised in vivo. By retaining these
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physiological functions, pharmaceutical interactions can be examined to predict in vivo responses [103,104].
However, because of using relatively large samples, the core of the suspended tissue strips can often become
hypoxic, which can hinder contractile readouts [104]. Another caveat with organ baths is the requirement of
fresh tissue for each experiment [105,106]. This prevents analysis from a single donor or genetic background,
which is achievable through 3D organoid culture. However, organ baths have been used to show that E. coli sti-
mulates the contractility of human colonic smooth muscle cells [107]. Thus, there is scope for advancing organ
bath techniques to study probiotic and pathogenic microbes ex vivo.
Organ-on-a-chip
To mimic key aspects of living organs, such as the multicellular structures, cell–cell and tissue–tissue interac-
tions, and the native microenvironment, organ-on-a-chip systems have been developed to incorporate micro-
ﬂuidic and microengineering technology [7,108]. The beneﬁt of developing such systems is that it provides a
platform to study the complex physiological and pathophysiological responses of tissues at an organ level, to
provide patients with quicker access to new medication. For example, microﬂuidics can be utilised to mimic
blood and nutrient ﬂow and maintain mucus transition in lung epithelia [108,109]. In addition, this system can
be exploited to complement animal studies and also more accurately predict pharmacological effects in patients
and, in the future, could be used to bypass the use of animal testing completely [110]. Organ-on-a-chip has
been developed for several organs, including the lung [111,112], heart [113,114], liver [115], neuron [116],
kidney [117,118], gut [14,43,119], blood vessel [120,121], tumour-on-a-chip [122], bone marrow-on-a-chip
[123], liver-tumour-bone marrow-on-a-chip [124], and liver-skin-intestine-kidney-on-a-chip [125]. These
systems can be extended to disease modelling, pharmaceutical analysis, drug development strategies
[6,118,122], and understanding host–microbe interactions [14,111,122]. For the purpose of this review, we will
discuss the use of organ-on-a-chip to study intestinal dynamics with particular focus on the gut microbiome.
The potential of these systems to accurately model drug uptake and metabolism in the human body has
recently been shown in the context of products produced by the microbiome. Vernetti et al. (2017) demon-
strated that a liver-intestine-kidney-on-a-chip system integrated with an intact blood–brain barrier/neurovascu-
lar unit sufﬁciently modelled in vivo trimethylamine (a by-product of the microbiome) metabolism.
Speciﬁcally, trimethylamine, microinjected into intestinal organoids, was found in the basolateral media and
was subsequently metabolised to trimethylamine N-oxide by the liver module and then secreted into the lumen
of the kidney module, which occurs in vivo. The study also revealed a novel ﬁnding that trimethylamine
N-oxide crosses the blood–brain barrier [126], emphasising the potential of such systems to further our under-
standing of human physiology.
Progression to gut-on-a-chip assays
The applications of gut-on-a-chip systems are still at the early stages of development [80]; however, they hold
great promise for studying the interactions between host and microbiome. Initial studies involved culturing a
monolayer of human epithelial Caco-2 cells inside a microﬂuidic device [127]. Although this microchip pro-
vided a vascular ﬂow over the cells, the ability of Caco-2 cells to reach conﬂuence was hindered. This was likely
caused from inherent faults within the system that did not allow large volumes of medium, and thus nutrients,
to be administered at a time, and resulted in cellular damage from dead cell debris, air bubbles, and the inabil-
ity to maintain a stable medium ﬂow [127]. These problems were circumvented by identifying optimal micro-
channel dimensions and appropriate Caco-2 cell density, which provided sufﬁcient nutrients and reduced shear
pressures that ultimately promoted Caco-2 cellular growth and normal barrier function [127]. This study high-
lights the importance of chip scaling, and this should be taken into consideration when developing novel
microﬂuidic devices in the future. More advanced microﬂuidic models have been subsequently developed,
based on the culture of Caco-2 cells under physiologically relevant conditions, including peristalsis-like
motions, intraluminal ﬂuid ﬂow, the use of 3D scaffolds, and support the growth of the naturally occurring
microbiome without diminishing cell viability [43]. These earliest models of gut-on-a-chip were adapted from
the advancements in lung-on-a-chip that enabled microﬂuidic systems to effectively model the cyclic breathing
motions of the human lung [111]. In 2012, a biomimetic human-gut-on-a-chip microdevice was developed
that consisted of two closely apposed microﬂuidic channels made from a self-adhesive elastomer, PDMS (that
is highly permeable to oxygen), creating a luminal and capillary channel [43]. Between the channels was a thin
elastic porous membrane coated with an ECM. A layer of Caco-2 cells was cultured on top of the ECM.
Culture medium was allowed to ﬂow through both channels to mimic in vivo ﬂuid ﬂow and shear stress.
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Peristaltic-like deformations were instigated by cyclic suction patterns to stretch and relax the porous mem-
brane [43]. The group reported that this human-gut-on-a-chip system allowed intestinal epithelial cells to
polarise, form 3D structures that closely resembled physical and functional features of human intestine and
created a high-integrity barrier against small molecules which was not achieved when cells were cultured using
Transwell models [43]. Additionally, this system allows the study of physiological gut functions in the presence
of relevant cues and interactions with the microﬂora. Caco-2 cells have been effectively co-cultured with a nat-
urally occurring intestinal microbe, Lactobacillus rhamnosus GG (LGG), at the luminal surface which improved
intestinal barrier function [43], which has been previously reported with probiotic bacteria strains in humans
[128]. Moreover, differentiated intestinal epithelium supported the growth of naturally occurring microbiota for
more than 2 weeks, which is in contrast with Transwell and organoid cultures where cell viability is often lost
within a few hours [12,14,43]. Taken together, these studies provide support for the use of gut-on-a-chip as a
tool for studying the mechanisms involved in intestinal function and the involvement of the normal gut micro-
biome. This system also has the potential to be exploited to study the development of disease in a more
human-relevant holistic environment, become a novel platform for drug development, and better predict
responses to therapy in clinical trials.
The potential of gut-on-a-chip was proved in a proof-of-principal study in 2016 when Kim et al. studied the
contribution of the microbiome to gut pathophysiology. Speciﬁcally, Caco-2 cells were co-cultured, with eight
living human commensal microbes that have previously been used in clinical trials of chronic inﬂammatory
bowel diseases [129]. Caco-2 cells displayed distinct gene expression proﬁles and phenotypes when cultured in
the presence of commensal microbes, which closely resembled the normal human ileum. Next, the group inves-
tigated whether gut-on-a-chip was sufﬁcient to model human intestinal inﬂammation, and what contribution
the gut microbiome played. Culturing Caco-2 cells with immune cells and non-pathogenic bacteria, to induce
pro-inﬂammatory cytokines, resulted in injury to the villus structure and impaired barrier function. By inde-
pendently controlling the addition of each cytokine to the system, the authors were able to elucidate that only
in the presence of interleukin-8 were the cytokines able to induce disease-promoting effects, which is not easy
to model using GEMMs. Furthermore, the extent of villus injury and compromised barrier function was
reduced and delayed by the addition of commensal probiotic microbes within the chip. Subsequently, antibiotic
therapies that are commonly used in clinic to treat intestinal inﬂammatory disease were added to protect the
epithelial cells from damage [14]. This provides direct evidence that gut-on-a-chip is efﬁcient in mimicking the
suppression of injury responses from bacteria and the immune system that are observed clinically [14]. More
importantly, the gut-on-a-chip assay provides a robust platform to identify the individual and combinational
effects of immune cells, commensal and pathogenic microbes, and epithelia and endothelial cells in a system
that closely resembles the in vivo environment. Although still not foolproof, this system enables the study of
intestinal physiology to identify mechanisms involved in gut pathophysiology and could be used to ﬁnd novel
therapeutics in a patient-speciﬁc manner in the future.
Quasi-Vivo® (Kirkstall)
Kirkstall have designed a system based on organ-on-a-chip models to produce a ‘system-on-a-plate’ array,
named Quasi-Vivo [130]. Quasi-Vivo technology aims at producing a down-scaled system of the human body
(through the use of allometrics, [131,132]), such that in vivo biochemical and physical stimuli, metabolic, volu-
metric and exchange rate relationships are retained in vitro [130]. Advantages of Quasi-Vivo over
organ-on-a-chip devices include limited cellular damage from high wall shear stresses [130,133] and the inher-
ent issue with bubble formation, which occurs in microﬂuidic systems, is overcome due to their intelligent
design features and size [130]. Preliminary ﬁndings from Kirkstall show that E. coli is viable within the
Quasi-Vivo system and, thus, has scope for future microbial analysis.
HuMix module
The HuMiX, human–microbial cross-talk module, composes three microﬂuidic chambers that are parallel to
one another and separated by semipermeable membranes. The alignment of these chambers provides a micro-
bial, epithelial, and perfusion chamber. The speciﬁc outlets and inlets of each chamber allow for the inoculation
of cell lines and, through the perfusion of cell growth media, can precisely control the physiochemical
conditions each chamber receives [24,134,135]. This set-up builds on previous systems such that it (1) has the
ability to simultaneously establish aerobic and anaerobic conditions and (2) can monitor oxygen levels in real
time [134].
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Several proof-of-concept studies have highlighted the potential HuMiX to enhance our understanding of
host–microbe cross-talk [134,135]. Speciﬁcally, Eain et al. report that HuMiX was sufﬁcient to co-culture
Caco-2 cells and microbial cells (LGG and Bacteroides caccae) under conditions that represented the in vivo
human GI tract, i.e. the maintenance of oxygen gradients either side of the epithelium. The arterial blood
supply was mimicked by the addition of an oxygen-rich media in the perfusion chamber, which provided epi-
thelial cells with oxygen from the basal surface. In doing so, the epithelium could grow in a shear-free environ-
ment, while anaerobes were present [135]. Additionally, the group were able to co-culture immune cells via the
perfusion chamber and are now focusing on developing a system, Immuno-HuMiX, to study the interactions
between the immune system and the intestinal microbiota in the human gut. However, the authors note that
despite the success in co-culture of human and microbial cells and the potential to extend this system to study
diet, drug screening, discovery, and delivery, these cell types cannot fully represent the complex cellular
makeup of the entire intestinal tract [134,135].
Bringing cell culture techniques closer to in vivo: future
directions
There is an abundance of unknown information with regard to the complexity of the gut microbiome and its
effect on the human host, which precludes the development of novel therapeutics for disease states. Recently,
signiﬁcant advancements in the scientiﬁc ﬁeld have attempted to unravel these host–gut microbiome interac-
tions. Although the reductionist approach of previous conventional modelling systems, such as static 2D and
3D cell culture, has improved our understanding of how the gut environment is relevant to both human physi-
ology and pathophysiology, advancements in technology have paved the way to microﬂuidic-based devices that
provide a more accurate representation of the in vivo microenvironment.
Microﬂuidic platforms, such as organ-on-a-chip, HuMiX, and other devices, have signiﬁcant potential in
advancing diagnostic, pharmaceutical, and nutritional industries with respect to earlier diagnosis, expedition of
drug development, and understanding the mechanisms that underpin dietary involvement in health and
disease. As these systems permit 3D co-culture of epithelial cells with underlying endothelium, immune cells,
and microbes with the inﬂuence of ﬂow and shear effects, they will be fundamental for further improving our
understanding of the host–microbiome interactions holistically. Having said that, there are many challenges
microﬂuidic technology still face today which require tweaking to better recapitulate the in vivo host–micro-
biome environment. Firstly, most systems heavily rely on the use of Caco-2 cells as a model of human intestinal
epithelium. While this cell line has been crucial in expanding our knowledge, Caco-2 cells were originally from
a human colorectal adenocarcinoma [7,24] and thus may have attributes that distinguish them from the
normal gut epithelium and any cross-talk between the host–gut microbiome may not be a true representation
of the native intestine. Speciﬁc issues of using Caco-2 cells to model gut epithelium are (1) Caco-2 cells, a
colon cancer-derived cell line, especially in the context of gut-on-a-chip assays, are used to study small intes-
tinal villus formation [12,14,43]. It is necessary to point out that the human colonic epithelium is not com-
posed of villi [136] and that cancer cells can behave differently from normal epithelial cells. (2) Only loose
observations can be made about gut physiology when using Caco-2 cells, as it is not clear which section of the
intestine, i.e. duodenum, ileum, jejunum or colon, is being modelled. It is important to know exactly which
region of the intestine is being modelled such that is mimics the architecture, cellular makeup and immune
responses that differs throughout the intestine. For example, the small intestine tends to be more acidic and
contains a single mucosal layer, whereas the colon consists of a protective thick double-layered mucus [137]
that harbours a higher bacterial density than the small intestine [136]. Therefore, without knowing which
section of intestine is being modelled, informed conclusions cannot be made. And (3) interactions between the
host and microbes that primarily inhabit the human colon are analysed in the context of epithelial villus forma-
tion and barrier integrity. Again, this is not a true representation of human gut physiology and thus emphasises
that Caco-2 studies should be limited when evaluating gut physiology. The progression in generating primary
epithelium and organoids from stem cells holds great promise for advancing these techniques to recreate the
cellular makeup and environmental conditions prevalent in the human gut, especially in light of the available
organoid monolayer Transwell culturing methods that utilises donor-speciﬁc tissue and enables co-culture with
microbes [42,76,77] and which has the potential to be translated to organ-on-a-chip and HuMiX modelling
systems. Secondly, most microﬂuidic devices have been sufﬁcient only in culturing aerobic microbes, which
does not reﬂect the anaerobic nature of the intestinal lumen [24,94]. The development of the state-of-the-art
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HuMiX system has provided a platform to culture aerobic-dependent epithelium in the presence of anaerobic
microbes, but further reﬁnement of this system is required to decipher the complex interactions between the
holistic gut environment (stroma, immune system, diet, microbiome, and metabolome) and the roles they play
in maintaining intestinal physiology and initiating and preventing intestinal diseases. The third challenge is a
technical issue. The material, PDMS, which is currently used to generate organ-on-a-chip microﬂuidic cham-
bers does not faithfully represent the physicochemical properties of the ECM that occur in vivo, and can often
preclude drug studies as small hydrophobic molecules are absorbed by the material [138,139]. In addition,
PDMS poses challenges for large-scale reproduction of microﬂuidic chambers. However, studies have been per-
formed to identify suitable alternative materials or surface coating techniques to combat this issue [140–142].
The challenge for the future is to develop a human-on-a-chip system [143,144], through the amalgamation
of the technologies described herein, in which several chambers can be interconnected to represent all aspects
of the human body (Figure 2), including factors such as the blood–brain barrier, aerobic–anaerobic nature of
the gut epithelium, and microbiome and disease states, i.e. tumours, to functionally mimic and study the
complex interactions between the circulatory, endocrine, digestive, immune, lymphatic, nervous, respiratory,
and urinary systems. Moreover, such a system would provide a holistic scope to investigate pathophysiological
conditions through subtle manipulations within chambers and will also provide a basis to systemically assess
drug interventions in the future.
Figure 2. A proposed microﬂuidic chip to model host–microbiome cross-talk.
An amalgamation of SynVivo, organ-on-a-chip, and HuMiX culturing systems has the potential to model the host–microbiome
interactions within the entire human body, in the presence of ﬂow and shear stresses (representative of a circulatory system).
© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and the Royal Society of Biology and distributed under the Creative Commons
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Summary
• Understanding, holistically, the mechanisms that underpin human physiology and pathophysi-
ology are hindered due to the difﬁculty in accessing organs, and a paucity of information on
the interactions between the host and microbiome.
• Conventional modelling systems such as 2D cell culture and Transwells fail to faithfully repre-
sent the in vivo human environment, especially in the context of studying host−microbiome
cross-talk. Emphasising a need for novel modelling systems that better recapitulate the
human body.
• Technological advancements involving microﬂuidic techniques has paved the way for exciting
organ-on-a-chip based culturing methods.
• Novel in vitro and ex vivo culturing techniques such as patient-derived organoid culture,
SynVivo®, Quasi-Vivo®, organ-on-a-chip and HuMiX systems, are beginning to provide more
clinically relevant platforms in which to better model and study human host-microbiome
interactions.
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